Micronized Amnion Joint Injection for Targeted Inflammation Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing wound coverings and medical applications using placental tissue components, such as amnion and chorion, are limited in their ability to effectively address inflammation in joints, and there is a need for a more targeted and efficient use of placental tissue components.
Innovation Solution
A pharmaceutical composition comprising micronized amnion particles, devoid of an intermediate layer, is developed for injection to alleviate inflammation in joints, utilizing a process that includes decontamination, dehydration, and micronization to maintain the integrity of the fibroblast layer and collagen types IV, V, and VII, along with bio-active factors like fibronectin and laminins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If placental tissue is processed using conventional methods, then the processing time is reduced, but the therapeutic efficacy and safety are compromised due to contamination and loss of beneficial components
Solution Approach 1:
The patent introduces an intermediary sterile processing system that mediates between the biological tissue and the final product. The sterile barrier film acts as a physical intermediary that prevents contamination while allowing controlled processing, thus maintaining both speed and safety.
Solution Approach 2:
The patent replaces conventional mechanical processing methods with a sterile barrier-based system. Instead of using mechanical means that risk contamination, the invention uses a controlled sterile environment with barrier films to achieve processing while maintaining therapeutic integrity.
2Duration of action of stationary object
If placental tissue is frozen for long-term storage, then the shelf life is extended, but the cellular structure and therapeutic properties are damaged
Solution Approach 1:
The patent changes the storage parameter from freezing to refrigeration at controlled temperatures (2°C to 8°C). This parameter change maintains the cellular structure and therapeutic properties while still providing extended shelf life through controlled temperature storage rather than extreme freezing.
Solution Approach 2:
The patent applies beforehand cushioning by using sterile barrier films and controlled atmosphere packaging before storage. This protective measure cushions the tissue from environmental damage and maintains cellular integrity during extended storage periods.
3Adaptability or versatility
If placental tissue is processed without immediate use, then logistical flexibility is improved, but bacterial growth and contamination risk increase
Solution Approach 1:
The patent uses sterile barrier films as intermediaries that allow the tissue to be processed and stored without immediate use while preventing bacterial contamination. The barrier film mediates between the need for logistical flexibility and the risk of bacterial growth.
Solution Approach 2:
The patent creates an inert sterile environment using controlled atmosphere packaging and sterile barriers. This inert environment prevents bacterial growth while allowing extended storage and logistical flexibility in transporting and storing the biological material.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Described herein are compositions composed of micronized placental components, extracts of micronized placental components, and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions and the extracts thereof are also described herein.